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PHARMACOKINETICS OF ASPIRIN IN MAN 
GERHARD LEVY, PHARM.D. 
Depar! men! of Pharmaceutics, School of Pharma cy, State University of New York at Buffalo, Buffalo, 
New York, U. S. A. 
Aspi rin (acetylsalicylic acid) is hydrolyzed in the 
body to salicylic acid , a process which probably 
occurs mainly in the liver and has a biologic 
half-life of about 15 min (1 j. Aspirin and salicylic 
acid have analgesic, antipyretic , and anti-inflam-
matory activity. Aspirin but not salicylic acid 
inhibits platelet aggregation; aspirin is a lso 
believed to be a better analgesic agent. The dosage 
regimen of aspirin for the treatment of arthritis 
and rheumatic fever is designed to produce salicy-
late concentrations between 20 and 30 mg per 100 
ml in the plasma, a concentration range which is 
generally accepted as optimum for safe and effec-
tive therapy. Concentrations above thilt range will 
frequently elicit salicylism , a syndrome which 
includes tinnitus. hyper entilation, and pyrexia 
and can be the precursor of serious and sometimes 
fatal intoxication . 
Aspi rin is rapidly absorbed from the gastrointes· 
tinal t rac t if given in aqueous solution. Its absorp-
tion ra te from capsules and tablets depends on the 
release characterist ics of these dosage form and is 
a function of t he drug 's rate of dissolution (2]. 
Enteric coated tablets cause erratic and oft en 
incomplete absorption of aspirin 13.4 J. The drug 
can produce gastri c erosions and bleeding, an 
effect which is local rather t.han systemic under 
clinical conditions and which can be reduced 
substantially by pharmaceutical formulation 
(5-8 J. uch red uction of gastrointestinal blood 10 s 
is achie\'ed by judicious use of appropriate atll· 
acids to reduce gastric acidity and/or by administer· 
ing aspirin in dilute aqueous solution. 
Following absorption of aspirin and its con\'er-
sion in the bod.\' to salicylic acid. t he latter is 
eliminated by five parallel and competing path. 
ways: renal excretion, conjugation with glycine t.o 
yield salicyluric acid. conjugation of the carboxyl 
or phenolic hydroxyl group to form two different 
glucuronides. and hydroxylation to gentisic acid. 
These metabolites are then excreted in the urine so 
that the drug can be almost completely recovered 
in the urine a salicylic acid and its metabolites. 
The two quantitatively most important path· 
ways of salicylate elimination in man , the forma· 
tion of sa licyluric acid and saJicyl phenolic glucu-
ronide. are of very low capacity and become 
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saturated in the usual dosage range employed in 
the treatment of inflammatory disease 19]. These 
non·linear pharmacokinetic characteristics have a 
num ber of important clinical implications [10): (a) 
t he time required to eliminate a given fraction of a 
dose of salicylate increases with increasing dose, 
(b) the steady-state sal icylate concentration in 
plasma increases more than proportionally with 
the dose rate , and (c) t he time required to attain 
steady-state salicylate concentrations increases 
with increasing dose. 
As the two major biotransformation pathways 
for salicylate elimination become saturated at 
higher doses of the drug , renal excretion of unme· 
tabolized salicylate becomes an increasingly 
important rOULe of elimination. The renal clear· 
ance of salicylate is very sensitive to urine pH; it 
can increase more than 20-fold as urine pH is 
increased from about 5 to about 8. lnterindividual 
differences in urine pH can therefore cause pro· 
nounced differences in plasma salicylate concen· 
trat ions among patients who receive t he same 
dosage regimen of aspirin [11). Some widely used 
antacids. such a aluminum·magnesium hydrox. 
ides. can increase urine pH significantly [12J and 
thereby cause a marked decrease of steady-state 
sa licyla te concentrations in plasma [131. 
Salicylic acid is readily transferred from preg-
nant women to their fetuses and is found fre· 
quently in the plasma of newborn infants (14 J. 
This may be a particular problem in women who 
receive regular do es of aspirin during their preg· 
nanc\' for ueatment of inflammatory disease 
beca~se t he newborn infant eliminates- the drug 
relatively more slowly than do adults [15 j. Salicy· 
late is also transferred from mother to nursing 
infant through the mother's milk l16 1. 
Aspirin dosage for the treatment of inflamma· 
torv disease must be individualized on the basis of 
pl';sma concentration monitoring and clinical reo 
sponse. There is evidence that an inadequate 
anti·inflammatory effect of aspi rin therapy is often 
due to inadequate dosage. 
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